129 related articles for article (PubMed ID: 34146854)
1. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.
Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X
Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
[TBL] [Abstract][Full Text] [Related]
3. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
[TBL] [Abstract][Full Text] [Related]
4. Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters.
Guo J; Miao G; Zhang W; Shi H; Lai P; Xu Y; Zhang L; Chen G; Han Y; Zhao Y; Liu G; Zhang L; Wang Y; Huang W; Xian X
Theranostics; 2024; 14(5):2036-2057. PubMed ID: 38505614
[No Abstract] [Full Text] [Related]
5. Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine.
Huang PP; Zhu WQ; Xiao JM; Zhang YQ; Li R; Yang Y; Shen L; Luo F; Dai W; Lian PA; Tang YX; Ran JL; Huang XS
Front Pharmacol; 2022; 13():935362. PubMed ID: 36034782
[TBL] [Abstract][Full Text] [Related]
6. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.
Feng Q; Baker SS; Liu W; Arbizu RA; Aljomah G; Khatib M; Nugent CA; Baker RD; Forte TM; Hu Y; Zhu L
Pathology; 2015 Jun; 47(4):341-8. PubMed ID: 25938357
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.
Jiang T; Zhang Y; Bai M; Li P; Wang W; Chen M; Ma Z; Zeng S; Zhou H; Jiang H
Toxicol Lett; 2019 Nov; 316():183-193. PubMed ID: 31437515
[TBL] [Abstract][Full Text] [Related]
8. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.
Rostama B; Beauchemin M; Bouchard C; Bernier E; Vary CPH; May M; Houseknecht KL
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302598
[TBL] [Abstract][Full Text] [Related]
9. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.
Lin MJ; Dai W; Scott MJ; Li R; Zhang YQ; Yang Y; Chen LZ; Huang XS
Oncotarget; 2017 Dec; 8(65):108802-108809. PubMed ID: 29312569
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.
Zhu Z; Cao T; Chen H; Zhang B; Lin C; Cai H
Food Chem Toxicol; 2023 Jun; 176():113757. PubMed ID: 37019375
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice.
Ress C; Dobner J; Rufinatscha K; Staels B; Hofer M; Folie S; Radlinger B; Adolph TE; Rubin EM; Roden M; Tilg H; Kaser S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):972-978. PubMed ID: 33549451
[TBL] [Abstract][Full Text] [Related]
13. Association of Serum Apolipoprotein A5 Concentration with Nonalcoholic Fatty Liver Disease in Ningbo, China.
Liu X; Xu P; Tao X; Li W; Hong Q; Cao Q
Contrast Media Mol Imaging; 2022; 2022():7015528. PubMed ID: 35854768
[TBL] [Abstract][Full Text] [Related]
14. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
Forte TM; Ryan RO
Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene.
Zhu C; Gao G; Song H; Xu F; Wu K; Liu X
Lipids Health Dis; 2016 Oct; 15(1):178. PubMed ID: 27724895
[TBL] [Abstract][Full Text] [Related]
17. The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Zhang J; Li Y; Wang B; Luo Y; Shi J; Zhao B
Med Sci Monit; 2020 Mar; 26():e921887. PubMed ID: 32191680
[TBL] [Abstract][Full Text] [Related]
18. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
Li M; Xu C; Shi J; Ding J; Wan X; Chen D; Gao J; Li C; Zhang J; Lin Y; Tu Z; Kong X; Li Y; Yu C
Gut; 2018 Dec; 67(12):2169-2180. PubMed ID: 28877979
[TBL] [Abstract][Full Text] [Related]
19. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
Li R; Chen LZ; Zhao W; Zhao SP; Huang XS
Biochem Biophys Res Commun; 2016 Sep; 478(3):1173-8. PubMed ID: 27544029
[TBL] [Abstract][Full Text] [Related]
20. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
